BIA Networking Lunch - Stevenage
Register today for another popular networking lunch, hosted by Stevenage Bioscience Catalyst. This is a great opportunity to hear from local members, meet new business contacts and grab a bite to eat. We are excited to be showcasing members the Stevenage region.
12.00 - 13.00 - Registration, networking and lunch
13.00 - 14.00 - Talks and discussion
14.00 - 14.30 - Further networking
Stevenage Bioscience Catalyst
Gunnels Wood Rd
Free for members and non-members
Since his appointment as Chief Executive of the BioIndustry Association in 2012, Steve has led major BIA campaigns for, amongst other things, improved access to finance, the refilling of the Biomedical Catalyst, anti-microbial resistance and the opportunity the sector presents to generalist long term investors. Steve champions the adaptive pathway approach to the licensing of new drugs, the need for Early Access and is particularly proud of the working relationship the BIA has established with the UK’s leading medical research charities.
A founder member of United Life Sciences, a strategic partnership representing over 1000 life science and healthcare member companies across the UK and internationally, Steve attends the UK’s Ministerial Industry Strategy Group, and sits on The Royal Society's Science, Industry and Translation Committee.
Beyond the UK Steve is a member of EuropaBio’s Board and its National Association Council and is a founder member of the International Confederation of Biotech Associations. An expert and regular commentator on the sector in the media and at industry-leading conferences Steve has worked both in biotech (as Senior Director at Genzyme UK and Ireland) and at the highest levels of UK government (as Special Advisor to John Reid, MP, during his time in Tony Blair’s government) for over 15 years. Steve was awarded the OBE in January 2017.
Dr Sally Ann Forsyth
Sally Ann was appointed as Chief Executive Office of Stevenage Bioscience Catalyst in March 2018 to lead it through its next phase of expansion.
Prior to taking up her role as CEO at Stevenage Bioscience Catalyst, Dr Forsyth was CEO for Norwich Research Park and the first Director of both Harwell Oxford and Colworth Science Park where she was responsible for leading their development as national science parks. Sally Ann began her career as a management trainee with Unilever holding a range of roles across technology licensing, venture capital and strategic alliance management.
She has a PhD in Molecular Biology from the University of Cambridge and is a qualified Chartered Global Management Accountant.
Lord Prior of Brampton
Lord Prior started as Chairman of UCLH NHS Foundation Trust in January 2018, taking over from Richard Murley.
Lord Prior was educated at Charterhouse School and Pembrooke College, Cambridge where he gained an exhibition and MA in Law. He worked for Lehman Brothers and Lazard Freres in New York training as an investment banker and qualified as a barrister in 1976, becoming a member of Gray’s Inn. He has held a number of senior positions within the industrial sector, including British Steel and was also elected MP for North Norfolk in 1997 and served until 2001.
He has served as Chairman of Norfolk & Norwich University Hospitals NHS Foundation Trust and also Chairman of the Care Quality Commission.
In 2015, he was appointed Parliamentary Under Secretary of State for Health and created a Life Peer. In December 2016, he was appointed as Parliamentary Under Secretary of State at the Department of Business, Energy & Industrial Strategy stepping down from this role in December 2017 to join UCLH.
In April 2018, he was appointed as Senior Advisor to Lazard Financial Advisory and will provide strategic counsel to Lazard and their clients, particularly in the healthcare sector.
Dr John Kelly
PhD from the Department of Thoracic Medicine, National Heart and Lung Institute, London, a BSc (Hons) Pharmacology from King’s College London and a BSc (Gen) Pharmacology and Chemistry from University College Dublin.5 years Postdoctoral at Cancer Research UK, (previously Imperial Cancer Research Fund), London, UK and Department of Pharmacology, University of South Alabama College of Medicine, Mobile, Alabama, USA.
Joined MRC Technology (now LifeArc) in October 2000:
Current position: Head of Business Development. Leading team, focus is on identifying early stage targets, small molecules and monoclonal antibodies for our drug discovery group, alliances between our drug discovery group and biotech/Pharma and the licensing of mature programmes to industry. Responsible for several licensing and antibody humanisation deals between LifeArc and Pharma/Biotech.
John will explain more about collaboration and funding opportunities with LifeArc.
Dr Richard Butt
Apollo Therapeutics is a collaborative venture between three world-leading UK universities (Imperial College London, University College London and the University of Cambridge) and three global pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Johnson & Johnson Innovation). Apollo provides committed translational funding and drug discovery expertise for novel therapeutics, sourced from the best of British academic research, accelerating them towards the clinic.
Apollo’s unique model provides quick, independent access to the resources to grow innovations and to champion the best of British academic research to industry. Apollo’s experienced team of industry scientists have a proven track record of therapeutic delivery and work in partnership with academics and industry partners, crafting each bespoke project to optimise the chances of long-term success. Apollo Therapeutics aims to create the therapies of the future by partnering with the UK’s globally leading academic science base and UK based Pharma industry to have a real impact on patient treatments and outcomes.
At the BIA Networking Lunch in Stevenage, Dr. Richard But, CEO of Apollo Therapeutics, will update on progress in developing and executing a broad portfolio of therapeutic approaches.